Relationship Between Polymorphism in Exon 8 of Estrogen Receptor Alpha Gene and Osteoporosis in Saudi Women

Lina M Al Neghery, Maha H Daghestani, Suphia M Sherbeenii, Sana A Ajaj, Mazen H Daghestani, Abdelmoneim Eldali, and Arjumand Warsy

1Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia
2Department of Diabetes and Endocrinology, King Fahad Medical City, Diabetes Center, Riyadh, Saudi Arabia
3Primary Care Clinics in King Khalid University Hospital, Riyadh, Saudi Arabia
4Department of Obstetrics & Gynecology, Umm-Al-Qura University, Makkah, Saudi Arabia
5Department of Biostatistics and Scientific Computing, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
6Central Laboratory of College of Science, King Saud University, Riyadh, Saudi Arabia

*Corresponding author: Lina M Al Neghery and Maha H Daghestani, Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia, Tel: +966565656781; E-mail: lina-al-neghery@hotmail.com

Received date: January 17, 2018; Accepted date: January 29, 2018; Published date: February 07, 2018

Copyright: © 2018 Al Neghery LM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Abstract

Objectives: Alternations in the estrogen receptor alpha (ERα) gene play an essential role in osteoporosis etiology. In this study, the relationship between a single nucleotide polymorphism (SNP) in ERα (G2014A) and osteoporosis in Saudi women were investigated.

Methods: In this research 40 females with osteoporosis and 41 healthy controls ranging in age from 35 to 75 years were examined. Demographic data were recorded, and blood samples were drawn in plain and in EDTA tubes for estimation of estrogens in the serum and extraction of DNA, respectively. The DNA was used to amplify the fragment of interest carrying the SNP in ERα by polymerase chain reaction (PCR). The PCR product was subjected to DNA sequencing.

Results: G2014A was polymorphic in Saudi women. Genotypes and allele frequencies were compared in the osteoporotic and non-osteoporotic groups. Although the genotypes of osteoporotic and non-osteoporotic subjects were significantly different (p<0.0157), the allelic frequency was not significantly different (p<0.519). Estrogen levels significantly differed between osteoporotic and non-osteoporotic subjects (mean ± SD: 46.6 ± 30.7 vs. 68.7 ± 47.1 pg/mL, p=0.0143). Importantly, a significant difference in waist-hip ratio in osteoporotic patient and the non-osteoporotic group was detected (0.8 ± 0.1 vs. 0.9 ± 0.0, p=0.0174).

Conclusion: Although there was no relationship between G2014A and osteoporosis in Saudi women, this study sheds light on another aspect, such as the significant difference in estrogen levels in these two groups. Furthermore, an advantageous effect of fat on bone mass was observed in the non-osteoporotic group.

Keywords: Osteoporosis; Bone mineral density; Estrogen receptor-α gene; Single-nucleotide polymorphism; Estrogen; Genetics

Introduction

Osteoporosis is a public health problem and affects the human skeleton as defined in Bone Health and Osteoporosis [1]. Low bone density, deterioration of bone tissue, and interruption of bone architecture are prominent features in osteoporosis patients. Consequently, bones tend to be weak and become more susceptible to fracture. The standard deviation of bone mineral density (BMD) is a customary measurement in osteoporosis diagnosis. According to the diagnostic classification of the World Health Organization (WHO), osteoporosis exists when a BMD of the hip or lumbar spine is less than or equal to 2.5 standard deviations below the mean BMD of an adolescent reference population. The risk of fracture is higher in those with the lowest BMD according to the WHO definition. However, these disorders affect an enormous number of people of both sexes and all races, and the prevalence is increasing as the population ages [2]. Women are the most likely to develop osteoporosis than men.

Several hormones play an important role in bone density regulation and distribution. Sex hormones are required for skeletal progress and establishing peak bone mass, and estrogen is involved in bone maintenance [3-5]. These effects involve controlling the maturation of growth plates, which tightly close during longitudinal growth; regulating bone metabolism,
particularly, cortical and cancellous; supporting reaching a peak bone mass, and inhibiting bone loss. These roles are required for the regulation of skeletal homeostasis for women [6-8]. The effects of estrogen on bone are mediated by its binding to specific estrogen receptors (ERs) located in the cytosol and nucleus. These receptors belong to the nuclear receptor hormone superfamily and are ligand-inducible transcription factors.

ERs mediate different mechanical response processes and function at different cellular levels; for instance, osteoblasts, osteoclasts, bone marrow stromal cells, and estrogen receptor alpha (ERα) affect cortical bone. In this regard, ERα in osteoblast progenitors is required for mechanosensing at the periosteum, but not in trabecular bone, indicating that osteoblast progenitors residing in different compartments respond to different cues such as growth factors and hormones. Previous studies in mice showed that apoptosis of osteocytes induced by estrogen deficiency is not uniform, but rather restricted to distinct anatomical areas of the cortical bone [9]. It seems to be the major receptor controlling estrogen effects on the bone and has an essential effect on bone turnover regulation and reducing the loss of bone mass [5,10,11]. Thus, osteoporosis appears to be a polygenic condition with multiple genes potentially playing minor roles [12]. The human ERα gene (also known as ESR1) is located on chromosome 6q25 and spans more than 140 kilobases [13,14].

In the Saudi population, studies have revealed that 30-50% of Saudi women above 40 years of age develop osteoporosis [15]. We hypothesized that single-nucleotide polymorphisms (SNPs) in ERα might affect the prevalence of osteoporosis in Saudi females. One such polymorphism is G2014A (SNP ID number: rs2228480), and studies have suggested that the G to A transition (G2014A) in exon 8 of the ERα, which changes the corresponding codon from ACG to ACA, has functional significance in affected women. Although the identified SNP does not alter the amino acid sequence, this SNP is located six nucleotides upstream of the stop codon TGA [16]. Moreover, genetic diversity is a major concern considering the necessity of preserving what may be a precious and irreplaceable richness, regarding new productive demands [17]. Conservation should be based on a deep knowledge of the genetic resources of the specific breed [18]. Therefore, it is important to characterize important genes using molecular tools. The maintenance of genetic diversity requires the adequate implementation of conservation priorities and sustainable management programs, which should be based on comprehensive information regarding the structure of the populations, including sources of genetic variability among and within breeds. Genetic diversity is an essential component for population survival, evolution, genetic improvement and adaptation to changing environmental conditions [19]. Moreover, genes affecting polygenic traits and characterizing them are difficult to identify [20,21]. The applications of molecular genetics have many important advantages [22], and determination of gene polymorphism is important [23-25], hence the goal of this study was to determine the relationship between this polymorphism and osteoporosis in Saudi women.

Osteoporosis and obesity are public health diseases involving several genetic and environmental factors. The precursor stem cell adipocytes and osteoblast differentiation involve the same pathways, and the hormones secreted from adipocytes affect the development of bone mass. Thus, assessing this relationship is important for understanding these disorders [26].

Materials and Methods

Subjects

The study population was comprised of Saudi women ranging in age from 35 to 75 years. The group included 40 osteoporotic women, and 41 healthy women were enrolled as controls. All women were non-smokers, non-alcoholic, and did not use estrogen replacement medicine. Furthermore, the study population groups divided into two subgroups of the postmenopausal women (aged above 50 years); the Non-osteoporotic postmenopausal women (n=16), and Osteoporotic postmenopausal women (n=22).

All volunteers in this study subjected to dual energy X-ray absorptiometry (DXA) which was the tool for assessment the BMD status and they donated blood samples after consent forms were obtained from the Department of Endocrinology and Diabetes in King Fahad Medical City in Riyadh (IRB#10-026).

Anthropometric measurements

For each member of the study group, anthropometric measurements were conducted using standardized techniques. These included measurements of height and weight, which were used to calculate body mass index (BMI, kg/m²) in addition to the waist and hip circumference to calculate the waist - hip ratio (WHR).

Bone mineral density measurement

BMD was measured by dual-energy X-ray absorptiometry using standardized and quality-assured equipment. BMD at the lumbar spine and right femoral neck were measured for each subject. The WHO has standardized the interpretation of BMD results based on a comparison of a patient’s BMD with the mean for a normal young adult population of the same sex and race [27]. Patient’s BMD values were calculated as a T-score, which is the number of standard deviations above or below the mean BMD for normal young adults as follows:

- Normal BMD: T-score no more than -1 SD below the young adult mean.
- Osteopenia: T-score between -1.0 and, -2.5.
- Osteoporosis: T-score equal to or less than -2.5.
- Severe osteoporosis: T-score below -2.5 for patients with a fragility fracture.

Measurement of residual estradiol concentrations

A plain red-top tube or serum separator tube was used to calculate circulating residual estradiol (E2) levels assayed using BioSource Enzyme Amplified Sensitivity Immunoassay E2-EASIA

Statistical analysis

Using SPSS version 20, mean, standard deviation, standard error of the mean was calculated for each parameter in the different groups [28]. Continuous variables between groups were compared by independent t-tests or analyses of covariance as appropriate. Categorical variables were compared by the chi-square test.

Results

Anthropometric, biochemical, and hormonal parameters were obtained for each group as showed in Table 1. The results were compared using the t-test, and the clinical and biochemical characteristics of osteoporotic patients vs. non-osteoporotic subjects were compared. We found a significant difference between WHR in osteoporotic patients and non-osteoporotic subjects (mean ± SD WHR: 0.8 ± 0.1 vs. 0.9 ± 0.0, p=0.0174). There was also a significant difference in circulating E2 level, where the osteoporotic patients had a lower circulating E2 than non-osteoporotic subjects (mean ± SD E2: 46.6 ± 30.7 vs. 68.7 ± 47.1 pg/mL, p=0.0143). While there was no significant difference at the level of estrogen hormone among postmenopausal women in the osteoporotic patient group and non-osteoporotic subjects as shown in Table 2. We tested the correlation coefficients between estrogen and age in osteoporotic patients and found a weakly decreasing linear relationship (r=-0.34409, p=0.0297). We tested the correlation between estrogen and BMI, which also showed a weak downhill linear relationship (r=-0.21832, p=0.1759). Similarly, for non-osteoporotic subjects, we tested the correlation coefficients between estrogen and age and found a moderately decreasing linear relationship (r=-0.42791, p=0.0053). On the other hand,
The correlation between estrogen and BMI showed a non-significantly increasing linear relationship \((r=0.21789, p=0.1711)\), as shown in Table 3.

### Table 1. Clinical and biochemical characteristics of osteoporotic patients and controls.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Clinical and biochemical characteristics of osteoporotic patients (Mean ± SD)</th>
<th>Non-osteoporotic patients (Mean ± SD)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>61.1 ± 7.6</td>
<td>58.5 ± 5.9</td>
<td>0.2639</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>32.9 ± 7.5</td>
<td>29.6 ± 4.5</td>
<td>0.1182</td>
</tr>
<tr>
<td>E2 Level (pg/mL)</td>
<td>38.3 ± 27.1</td>
<td>48.5 ± 20.0</td>
<td>0.1891</td>
</tr>
<tr>
<td>WHR</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Correlation coefficients between estrogen levels with age and BMI in osteoporotic patients and non-osteoporotic group.

<table>
<thead>
<tr>
<th>rs2228480</th>
<th>SNP</th>
<th>Variation</th>
<th>Osteoporotic group</th>
<th>Non-osteoporotic group</th>
<th>OR</th>
<th>CI</th>
<th>(\chi^2)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GG</td>
<td>33(0.825)</td>
<td>38(0.93)</td>
<td>Ref</td>
<td>0.0157</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA</td>
<td>7(0.175)</td>
<td>1(0.02)</td>
<td>25</td>
<td>0.75-81</td>
<td>5.83</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>0</td>
<td>2(0.05)</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA+AA</td>
<td>7(0.086)</td>
<td>3(0.037)</td>
<td>2.687</td>
<td>0.64-11.2</td>
<td>1.94</td>
<td>0.166</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>77(0.94)</td>
<td>73(0.91)</td>
<td>0.677</td>
<td>0.449-4.86</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>5(0.06)</td>
<td>7(0.09)</td>
<td>1.477</td>
<td>0.206-2.229</td>
<td>0.42</td>
<td>0.519</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Alleles and genotype distributions based on G2014A SNP in osteoporotic patients and non-osteoporotic subjects.

The study population was divided into three groups based on the genotypes of G2014A and the value of the anthropometric parameters, BMD and hormone levels were separately calculated. The results in the different genotypes were compared using Students 't' test. The results are presented in Table 5. A significant relationship was observed between the AA genotype and lumbar T-score \((p=0.032)\).

### Table 5. Relationship between rs2228480 genotypes and study variables for our subjects.

<table>
<thead>
<tr>
<th>SNP</th>
<th>Variation</th>
<th>Osteoporotic group</th>
<th>Non-osteoporotic group</th>
<th>OR</th>
<th>CI</th>
<th>(\chi^2)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2228480</td>
<td>GG</td>
<td>33(0.825)</td>
<td>38(0.93)</td>
<td>Ref</td>
<td>0.0157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA</td>
<td>7(0.175)</td>
<td>1(0.02)</td>
<td>25</td>
<td>0.75-81</td>
<td>5.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>0</td>
<td>2(0.05)</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA+AA</td>
<td>7(0.086)</td>
<td>3(0.037)</td>
<td>2.687</td>
<td>0.64-11.2</td>
<td>1.94</td>
<td>0.166</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>77(0.94)</td>
<td>73(0.91)</td>
<td>0.677</td>
<td>0.449-4.86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>5(0.06)</td>
<td>7(0.09)</td>
<td>1.477</td>
<td>0.206-2.229</td>
<td>0.42</td>
<td>0.519</td>
<td></td>
</tr>
</tbody>
</table>

OR= odd error, CI=confidence interval, Signification value=p ≤ 0.05

The study population was divided into three groups based on the genotypes of G2014A and the value of the anthropometric parameters, BMD and hormone levels were separately calculated. The results in the different genotypes were compared using Students 't' test. The results are presented in Table 5. A significant relationship was observed between the AA genotype and lumbar T-score \((p=0.032)\).

### Table 5. Relationship between rs2228480 genotypes and study variables for our subjects.

<table>
<thead>
<tr>
<th>SNP</th>
<th>Variation</th>
<th>Osteoporotic group</th>
<th>Non-osteoporotic group</th>
<th>OR</th>
<th>CI</th>
<th>(\chi^2)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2228480</td>
<td>GG</td>
<td>33(0.825)</td>
<td>38(0.93)</td>
<td>Ref</td>
<td>0.0157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA</td>
<td>7(0.175)</td>
<td>1(0.02)</td>
<td>25</td>
<td>0.75-81</td>
<td>5.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>0</td>
<td>2(0.05)</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA+AA</td>
<td>7(0.086)</td>
<td>3(0.037)</td>
<td>2.687</td>
<td>0.64-11.2</td>
<td>1.94</td>
<td>0.166</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>77(0.94)</td>
<td>73(0.91)</td>
<td>0.677</td>
<td>0.449-4.86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>5(0.06)</td>
<td>7(0.09)</td>
<td>1.477</td>
<td>0.206-2.229</td>
<td>0.42</td>
<td>0.519</td>
<td></td>
</tr>
</tbody>
</table>

OR= odd error, CI=confidence interval, Signification value=p ≤ 0.05
remains unknown whether these differences were related to differences in bone mass from childhood or because of postmenopausal bone loss. Thus, additional studies are needed to confirm this association [16].

This G2014A SNP has been implicated in osteoporosis development in Mexican women in a study of 70 osteoporotic and 70 non-osteoporotic women. The frequencies of the ‘G’ allele and GG genotype were considerably higher in osteoporotic than in non-osteoporotic Mexican women, suggesting an association between the ‘G’ allele and osteoporosis. Women homozygous for the ‘G’ allele displayed the lower lumbar BMD and T-score values than women with the GA and AA genotypes. However, additional molecular studies are required to clarify this point [32-34]. While we found no significant differences between the frequencies of the ‘A’ and ‘G’ alleles in the different groups and osteoporosis in this study, the genotype frequencies showed some differences. Multiple factors may influence the polymorphism association, such as differences in age, menopausal status, inadequate sample size, ethnicity, and mixed populations.

A large number of studies have attempted to evaluate the association between ERα alleles and BMD [35] and some studies found an association between ERα alleles and ultrasound properties of bones [36]. We found an association between the G2014A genotype and BMD, and AA which was significantly associated with the lumbar T-score (p=0.032), which may agree with the results of previous studies.

Finally, our study provides insight into the differences between our population frequencies and frequencies in other populations. Most frequently observed allele and genotype frequency differences between populations have likely resulted from diversity in sample sizes and ethnicities or environmental backgrounds. These studies demonstrate the importance of investigating SNPs, which can impact the risk of diseases such as osteoporosis.

Furthermore, several lines of evidence have revealed a correlation between estrogen, which is part of the endocrine system that regulates BMD, and the occurrence of osteoporosis. Estrogen deficiency implicates menopause development, which leads to increased bone resorption and eventual acceleration of osteoporosis [37-39]. However, clinical trials showed that estrogen supplementation markedly delays osteoporosis development [40]. Laboratory experiments in animals revealed a significant decrease in bone mass after ovariotomy [41]. Some studies showed that the likelihood of osteoporosis in men was related to a failure in altering testosterone to estrogen ratio because of aromatase deficiency [42]. However, men with osteoporosis and open epiphyses are responsive to estrogen but not testosterone therapy [43]. These studies support the importance of estrogen and demonstrate that its receptor, which is localized in both the cytosol and nucleus of bone cells, protects against osteoporosis [44].

A significant difference in the level of estrogen hormone (p=0.0143) among osteoporotic and non-osteoporotic women aged between 35 and 75 years was found in this study. However, we found no significant difference in estrogen hormone among postmenopausal women in the osteoporosis patient group and non-osteoporotic group. A study in Thailand study found no
significant difference in circulating estrogen among postmenopausal women [15]. This discrepancy occurred because estrogen hormone regressed in postmenopausal women until the levels of estrogen became convergent in the same age group.

Indeed, according to epidemiological studies, the correlation between BMI and bone mass remains unclear, while another group of studies found that higher BMI was correlated with high bone mass. Furthermore, adipocytes are important sources of estrogen in women for inhibiting bone resorption [45-47]. Thus, we found a correlation between estrogen and BMI in the non-osteoporotic group, although the correlation was weak (r=0.21789); these results support that estrogen levels are involved in the complex relationship between BMI and osteoporosis. We also evaluated an additional aspect of fat mass and osteoporosis and found a significant difference between our subjects and WHR, in which fat likely benefits bone (p=0.0174). In contrast, another study evaluated 4489 Caucasian and 1988 healthy unrelated Chinese premenopausal women aged 19.6-45.1 years and 19.1-90.1, respectively. Their study used dual-energy X-ray absorptiometry scanners to assess osteoporosis and percentage fat mass, which is the ratio of the fat mass divided by total body weight to determine the obesity of subjects. The study showed that an increased fat mass might not have a beneficial effect on bone mass [48,49]. Although their study analyzed the effect of mechanical loading on bone mass, differences in measurement and analysis methods may explain the different results.

In conclusion, although we found no association between the G2014A SNP of the ERα and osteoporosis in Saudi women, genetic heterogeneity was present and showed inconsistent results with previous studies. Overall, this study sheds light on another aspect, such as the significant difference in estrogen levels in these two groups. Furthermore, an advantageous effect of fat on bone mass was observed in the non-osteoporotic group.

Acknowledgements

We are grateful to the patients and control subjects for their participation in our study. We would like to also thank Research Center of the Female Scientific and Medical Colleges at King Saud University for supporting the study.

References


